The Applications of Pharmacogenomics to Neurological Disorders

Title:The Applications of Pharmacogenomics to Neurological Disorders

Volume: 14 Issue: 7

Author(s): C. Gilman, C. McSweeney and Y. Mao

Affiliation:

Keywords: Genome wide association study (GWAS), neurodegenerative diseases, pharmacogenomics, psychiatric disorders.

Abstract: The most common neurological disorders, including neurodegenerative diseases and psychiatric disorders, have received recent attention with regards to pharmacogenomics and personalized medicine. Here, we will focus on a neglected neurodegenerative disorder, cerebral ischemic stroke (CIS), and highlight recent advances in two disorders, Parkinson’s disease (PD) and Alzheimer’s diseases (AD), that possess both similar and distinct mechanisms in regards to potential therapeutic targets.

In the first part of this review, we will focus primarily on mechanisms that are somewhat specific to each disorder which are involved in neurodegeneration (i.e., protease pathways, calcium homeostasis, reactive oxygen species regulation, DNA repair mechanisms, neurogenesis regulation, mitochondrial function, etc.). In the second part of this review, we will discuss the applications of the genome-wide technology on pharmacogenomics of mental illnesses including schizophrenia (SCZ), autism spectrum disorders (ASD), attention deficit hyperactivity disorder (ADHD), and obsessive compulsive disorder (OCD).

Cite this article as:

Gilman C., McSweeney C. and Mao Y., The Applications of Pharmacogenomics to Neurological Disorders, Current Molecular Medicine 2014; 14 (7) . https://dx.doi.org/10.2174/1566524014666140811115900